$6.580
-0.039 (-0.60%)At close
SPRC News
SPRC Events
SciSparc Subsidiary and Clearmind File New Patent Application
SciSparc (SPRC) announced that its subsidiary, NeuroThera Labs, and Clearmind Medicine (CMND) have published a U.S. patent application covering a novel combination of MDMA and N-acylethanolamines, such as palmitoylethanolamide, or PEA, for use in methods of treating post-traumatic stress disorder, or PTSD, anxiety, and eating disorders. The publication marks a significant intellectual property milestone resulting from the ongoing collaboration between NeuroThera and Clearmind. Through this collaboration, NeuroThera's PEA technology is integrated into Clearmind's psychedelic-derived therapeutic programs, contributing to a joint intellectual property portfolio that includes thirteen published patent applications generated through the NeuroThera-Clearmind collaboration globally. The newly published application includes embodiments relating to the potential use of PEA in combination with MDMA, including potential effects on MDMA's therapeutic potency, required dosing, associated side effects and therapeutic window. On July 14, the FDA finalized its guidance, "Psychedelic Drugs: Considerations for Clinical Investigations." The guidance provides considerations for sponsors developing psychedelic drugs for medical conditions, including psychiatric disorders and substance use disorders. The FDA's final guidance explicitly includes MDMA within its definition of psychedelic drugs, describing the category as including classic psychedelics as well as "entactogens or empathogens such as 3,4-methylenedioxymethamphetamine."
Scisparc Ltd Trading Halted Due to Volatility
Scisparc Ltd trading halted, volatility trading pause
SciSparc Establishes Scientific Advisory Board for Agentic AI Market
SciSparc announced that its board of directors has made a decision to target the agentic artificial intelligence market. As part of this initiative, the company has decided to establish a scientific advisory board to focus on AI and cybersecurity. SciSparc is currently evaluating opportunities and is in discussions with several companies active in the agentic AI field.
SciSparc Subsidiary NeuroThera Labs Initiates Phase IIb Trial for SCI-110 in Germany
SciSparc announced that its subsidiary NeuroThera Labs announced the initiation of its Phase IIb clinical trial site at Hannover Medical School, Hanover, Germany, for SCI-110, its proprietary cannabinoid-based treatment candidate for Tourette Syndrome in adults.
SciSparc Collaborates with Clearmind to File Patent for Depression Treatment
The company states: "SciSparc has reported that pursuant to NeuroThera's ongoing collaboration with Clearmind Medicine Inc., a patent application has been filed by Clearmind with the Intellectual Property Department in Hong Kong, China, for a innovative combination therapy designed to treat major depressive disorder. This innovative treatment combines Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide sourced by NeuroThera. The patent filing underscores the promise of this MEAI-PEA synergy as a non-hallucinogenic neuroplastogen option for combating depression, a condition affecting more than 332 million people globally, according to the World Health Organization article titled "Depressive Disorder (Depression)", published in August 2025 Given the anticipated mechanism of action, this therapy could provide a more accessible, safer, and affordable alternative to existing antidepressants, including Selective Serotonin Reuptake Inhibitors and other conventional options."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.